These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33904486)

  • 1. Acute Acalculous Cholecystitis in a Multiple Sclerosis Patient Treated with Natalizumab.
    Lambea-Gil A; Fumanal-Idocin L; Sebastián-Torres B; Saldaña-Inda I; Huici-Polo P; Alarcia-José-Ramon-Ramon Ara-Callizo R
    Neurol India; 2021; 69(2):495-496. PubMed ID: 33904486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.
    Croteau D; Flowers C; Kulick CG; Brinker A; Kortepeter CM
    Neurology; 2018 May; 90(18):e1548-e1552. PubMed ID: 29602912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.
    Berek K; Paganini C; Hegen H; Bsteh G; Grams A; Auer M; Berger T; Deisenhammer F; Di Pauli F
    Wien Med Wochenschr; 2022 Nov; 172(15-16):373-378. PubMed ID: 35142953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
    Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
    Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of rheumatoid arthritis following exposure to natalizumab.
    Su E; Novic J; Han MH
    Mult Scler Relat Disord; 2020 May; 40():101936. PubMed ID: 31982664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Acalculous Cholecystitis after Measles.
    Karaşahin EF; Karaşahin Ö
    Arch Iran Med; 2021 Jun; 24(6):505-507. PubMed ID: 34488314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
    Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
    Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune reconstitution inflammatory syndrome and natalizumab-Is it possible before removing the drug?
    Mulero P; Neri MJ; Rodriguez M; Arenillas JF; Téllez N
    Mult Scler Relat Disord; 2014 Sep; 3(5):659-61. PubMed ID: 26265277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off.
    Leodori G; Mancuso M; Maccarrone D; Tartaglia M; Ianniello A; Certo F; Ferrazzano G; Malimpensa L; Belvisi D; Pozzilli C; Berardelli A; Conte A
    Sci Rep; 2024 Jul; 14(1):17654. PubMed ID: 39085330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute acalculous cholecystitis after abdominal wall repair (Rives-Stoppa).
    Reurings JC; Diaz RP; Penninga L; Nellensteijn DR
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24739656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.
    Giacoppo S; Ruscica M; Grimaldi LM; Bramanti P; Mazzon E
    Med Sci Monit; 2017 Sep; 23():4230-4240. PubMed ID: 28864818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Foley RW; Tagg NT; Schindler MK; Fenton KM; Reich DS; Cortese I; Mowry EM
    Mult Scler; 2017 Sep; 23(10):1424-1427. PubMed ID: 28639536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent skin infections associated with natalizumab treatment.
    Oliveira DS; Castro AR; Ruano L
    Neurol Sci; 2023 Mar; 44(3):1093-1095. PubMed ID: 36331655
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute acalculous cholecystitis in a patient with primary Epstein-Barr virus infection: a case report and literature review.
    Agergaard J; Larsen CS
    Int J Infect Dis; 2015 Jun; 35():67-72. PubMed ID: 25887813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?
    Van Obberghen EK; Cohen M; Rocher F; Lebrun-Frenay C
    Rev Neurol (Paris); 2017 Apr; 173(4):222-224. PubMed ID: 28372806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute acalculous cholecystitis with pericholecystitis in a patient with Epstein-Barr Virus infectious mononucleosis.
    Chalupa P; Kaspar M; Holub M
    Med Sci Monit; 2009 Feb; 15(2):CS30-33. PubMed ID: 19179974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab.
    Beume LA; Dersch R; Fuhrer H; Stich O; Rauer S; Niesen WD
    J Clin Neurosci; 2015 Feb; 22(2):400-1. PubMed ID: 25150761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute acalculous cholecystitis in a Lebanese girl with primary Epstein-Barr viral infection.
    Majdalani M; Milad N; Sahli Z; Rizk S
    BMJ Case Rep; 2016 Apr; 2016():10.1136/bcr-2015-213829. PubMed ID: 27090538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S; Comar M; Ferrante P
    Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.